Coastlands Capital LP has filed an amended Schedule 13G, revealing a significant change in its stake in Azora Therapeutics, Inc. The filing indicates that Coastlands no longer beneficially owns more than 5% of any class of securities of the issuer, marking a strategic shift in its investment approach.

This filing, dated November 3, 2026, highlights that Coastlands Capital LP, along with its affiliates, collectively holds 655,975 shares of Azora Therapeutics, which represents 4.99% of the company. The filing notes that this change is classified as an exit filing, as the reporting persons have reduced their ownership below the 5% threshold.

Background

Coastlands Capital LP is a Delaware limited partnership based in San Francisco, California. The firm, which operates in the investment advisory sector, has made several recent filings, including a Schedule 13G/A on November 2, 2026, and a Schedule 13G on October 26, 2026. The company focuses on managing investments and has been involved in various sectors, including pharmaceuticals.

What the Filing Says

The amended filing states, "This Amendment No. 2 to Schedule 13G constitutes an exit filing for the Reporting Persons, as the Reporting Persons no longer beneficially own more than 5 percent of any class of securities of the Issuer." This statement confirms the reduction in ownership and clarifies the status of their investment.

Impact

This change may impact other investors and stakeholders within Azora Therapeutics and the broader pharmaceutical preparations sector. As Coastlands Capital LP adjusts its holdings, it may influence market perceptions and strategies among competitors and other investment firms.

What's Next

The filing does not say what happens next.